DUBLIN--(BUSINESS WIRE)--The "Raynauds Disease - Pipeline Review, H2 2017" report has been added to Research and Markets' offering.
Raynauds Disease - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Raynauds Disease (Cardiovascular), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Raynauds Disease (Cardiovascular) pipeline guide also reviews of key players involved in therapeutic development for Raynauds Disease and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II and Preclinical stages are 1, 2 and 1 respectively. Similarly, the Universities portfolio in Unknown stages comprises 1 molecules, respectively.
Raynauds Disease (Cardiovascular) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Key Topics Covered:
- Introduction
- Raynauds Disease - Overview
- Raynauds Disease - Therapeutics Development
- Pipeline Overview
- Pipeline by Companies
- Pipeline by Universities/Institutes
- Products under Development by Companies
- Products under Development by Universities/Institutes
- Raynauds Disease - Therapeutics Assessment
- Assessment by Target
- Assessment by Mechanism of Action
- Assessment by Route of Administration
- Assessment by Molecule Type
- Raynauds Disease - Companies Involved in Therapeutics Development
- Allergan Plc
- Apricus Biosciences Inc
- Covis Pharmaceuticals Inc
For more information about this report visit https://www.researchandmarkets.com/research/7lb4rb/raynauds_disease
